Viking Therapeutics (VKTX) Interest Expenses (2014 - 2015)

Viking Therapeutics has reported Interest Expenses for 13 years, with the latest figure at $131.0 million in Q2 2026.

• Quarterly Interest Expenses rose 71.0% year-over-year to $131.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $131.0 million (up 71.0% YoY) and the FY2025 annual result came in at $114.0 million, down 30.53% from the prior year.
• Interest Expenses grew to $131.0 million in Q2 2026 per VKTX's latest filing, from $101.0 million in the prior quarter.
• Over five years, Interest Expenses peaked at $60.3 billion in Q1 2023 and troughed at $1.8 million in Q3 2022.
• A 5-year average of $7.5 billion and a median of $107.5 million in 2025 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2023 and 2024: Interest Expenses surged 3368241.71% in 2023, then plunged 99.55% in 2024.
• Over 5 years, Interest Expenses stood at $20.5 million in 2022, then jumped by 203.24% to $62.2 million in 2023, then jumped by 163.78% to $164.1 million in 2024, then slumped by 30.53% to $114.0 million in 2025, then rose by 14.91% to $131.0 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $131.0 million, $101.0 million, and $114.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.